Molecular Inconsistencies in a Fragile X Male with Early Onset Ataxia by Hwang, YT et al.
genes
G C A T
T A C G
G C A T
Case Report
Molecular Inconsistencies in a Fragile X Male with
Early Onset Ataxia
Yun Tae Hwang 1,2, Tracy Dudding 3,4, Solange Mabel Aliaga 5,6,7, Marta Arpone 5,6,
David Francis 5, Xin Li 5, Howard Robert Slater 5,6, Carolyn Rogers 3, Lesley Bretherton 8,9,10,
Desirée du Sart 11, Robert Heard 12,13,† and David Eugeny Godler 7,*,†
1 Department of Neurology, Gosford Hospital, Gosford 2250, Australia; y.hwang@ucl.ac.uk
2 Institute of Neurology, University College London, London WC1N 3BG, UK
3 Genetics of Learning Disability Service, Hunger Genetics, Waratah 2298, Australia;
Tracy.Dudding@hnehealth.nsw.gov.au (T.D.); Carolyn.Rogers@hnehealth.nsw.gov.au (C.R.)
4 Grow Up Well Priority Research Centre, University of Newcastle, Waratah 2308, Australia
5 Cyto-molecular Diagnostic Research Laboratory, Victorian Clinical Genetics Services and
Murdoch Childrens Research Institute, Royal Children’s Hospital, Melbourne 3052, Australia;
solange.aliagavera@mcri.edu.au (S.M.A.); marta.arpone@mcri.edu.au (M.A.);
david.francis@vcgs.org.au (D.F.); xin.li@mcri.edu.au (X.L.); howard.slater@vcgs.org.au (H.R.S.)
6 Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne 3010, Australia
7 Molecular and Cytogenetics Laboratory, INTA University of Chile, Santiago 7830490, Chile
8 Psychology Service, Royal Children’s Hospital, Melbourne 3052, Australia; Lesley.Bretherton@rch.org.au
9 Melbourne School of Psychological Sciences, University of Melbourne, Melbourne 3052, Australia
10 Child Neuropsychology, Murdoch Childrens Research Institute, Royal Children’s Hospital,
Melbourne 3052, Australia
11 Molecular Genetics Laboratory, Victorian Clinical Genetics Services and Murdoch Childrens
Research Institute, Royal children’s Hospital, Melbourne 3052, Australia; dusart.desiree@mcri.edu.au
12 Faculty of Medicine, University of Newcastle, Newcastle 2303, Australia; morkeu@gmail.com
13 Westmead Millennium Institute, University of Sydney, Westmead 2145, Australia
* Correspondence: david.godler@mcri.edu.au; Tel.: +61-3-8341-6496; Fax: +61-3-9348-1391
† These authors contributed equally to this work.
Academic Editor: Mark Hirst
Received: 12 May 2016; Accepted: 13 September 2016; Published: 21 September 2016
Abstract: Mosaicism for FMR1 premutation (PM: 55–199 CGG)/full mutation (FM: >200 CGG)
alleles or the presence of unmethylated FM (UFM) have been associated with a less severe fragile X
syndrome (FXS) phenotype and fragile X associated tremor/ataxia syndrome (FXTAS)—a late onset
neurodegenerative disorder. We describe a 38 year old male carrying a 100% methylated FM detected
with Southern blot (SB), which is consistent with complete silencing of FMR1 and a diagnosis of
fragile X syndrome. However, his formal cognitive scores were not at the most severe end of the
FXS phenotype and he displayed tremor and ataxic gait. With the association of UFM with FXTAS,
we speculated that his ataxia might be related to an undetected proportion of UFM alleles. Such UFM
alleles were confirmed by more sensitive PCR based methylation testing showing FM methylation
between 60% and 70% in blood, buccal, and saliva samples and real-time PCR analysis showing
incomplete silencing of FMR1. While he did not meet diagnostic criteria for FXTAS based on MRI
findings, the underlying cause of his ataxia may be related to UFM alleles not detected by SB,
and follow-up clinical and molecular assessment are justified if his symptoms worsen.
Keywords: fragile X syndrome; FMR1; FXTAS; ataxia; tremor; methylation; mosaicism; AmplideX;
Southern blot; RNA toxicity
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1. Introduction
CGG expansions of more than 200 CGG repeats within the 5′untranslated end of FMR1 are termed
full mutations (FM) and are associated with epigenetic silencing of the FMR1 gene [1]. Absence
of FMR1 transcription usually results from abnormal methylation of the FMR1 promoter [2] and is
associated with loss of FMR1 protein (FMRP). Absence of FMRP, which is a protein essential for normal
neurodevelopment, is the primary cause of the fragile X syndrome (FXS) [3]. FXS is the most common
monogenic cause of autism and intellectual disability [4] with a prevalence of 1 in 4000 males and 1 in
8000 females in the general population [5].
The more common CGG triplet expansions of 55 to 199 CGG repeats are termed premutations
(PM) and are found in approximately 1 in 450 males and 1 in 150 females in the general population [6].
In contrast to FM, PM alleles have a completely unmethylated FMR1 promoter similar to normal
size alleles with less than 44 repeats [7], but are associated with elevated FMR1 mRNA levels and
paradoxically impaired translation and decreased FMRP levels [8]. Increased FMR1 transcription
usually leads to gain-of-function toxicity resulting in aggregation of proteins by the excessive
mRNA, formation of ubiquitin-positive inclusion bodies in the brain and other tissues, mitochondrial
dysfunction, and excessive cell death [9–11]. This molecular cascade has been postulated to be a major
contributing factor in the development of PM-specific disorders including fragile X tremor and ataxia
syndrome (FXTAS)—a neurodegenerative disorder affecting up to 45% PM males and 17% PM females
over the age of 50 [12]. Other molecular contributors to PM specific phenotypes have been suggested
to be decreased FMRP levels [8], over-expression of long non-coding RNA of ASFMR1/FMR4 [11],
FMR5, and FMR6 [13], and repeat associated non-ATG translation [14].
Although FXS and FXTAS are regarded as distinct disorders, several lines of evidence now suggest
that they can be comorbid [15]. Specifically, diagnosis of probable FXTAS has been reported in three
FM male cases with completely unmethylated FM alleles in blood [16–18]. While significant increases
in FMR1 mRNA were reported in blood from all three cases, CGG size testing in other peripheral
tissues identified PM/FM mosaicism for one of these [18]. More recently, we have described tissue
mosaicism for FM methylation and a microdeletion proximal to the CGG repeat in a 33 year old male
with clinical and MRI findings consistent with FXTAS, which is the youngest case reported to date of
probable FXTAS [19].
In this study, we describe a 38 year old FXS male with a fully methylated FMR1 promoter in blood,
detected using Southern blot analysis of the NruI restriction site within the FMR1 CpG island. This
approach is the gold standard FXS diagnostic test where full methylation is understood to indicate
complete silencing of FMR1 [20]. However, this result was at odds with methylation analysis of other
regions within the FMR1 promoter and FMR1 expression that was reduced, but not silenced. While
this individual did not meet the diagnostic criteria for FXTAS, he did show early onset ataxia in his 30s.
2. Experimental Section
2.1. Ethics Approval
The follow-up clinical and molecular assessments consequent to assessment of his tremor and
ataxia symptoms in the neurology clinic were conducted as part of the FREE FX study, approved by
The Royal Children’s Hospital Research and Ethics Committee.
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2.2. Sample Processing
CGG triplet repeat sizing and methylation testing were performed on 15 mL of peripheral
blood collected in EDTA tubes, saliva samples collected using the Oragene® DNA Self-Collection
Kit (DNA Genotek, Ottawa, ONT, Canada), and buccal samples collected using the Master Amp
Buccal Swab Brush kit (Epicentre Technologies, Madison, WI, USA). DNA was isolated from these
sample types using the NucleoSpin® Tissue genomic DNA extraction kit (Machery-Nagel, Duren,
Germany). Five mL of blood was used for peripheral blood mononuclear cell (PBMC) isolation
using Ficoll gradient separation [10]. RNA was extracted from the isolated PBMCs using RNeasy kit
(Qiagen Global, Waldbronn, Germany) as per the manufacturer’s instructions.
2.3. Molecular Analyses
Initial CGG repeat sizing in all samples was performed using polymerase chain reaction (PCR) as
previously described [21]. Methylation-sensitive Southern blot was used to confirm presence of a FM
allele and to perform methylation analysis of the NruI restriction site located within the CpG island 5′ of
the CGG expansion, which is the “gold standard” recommended in FXS diagnostics [20]. Methylation
controls included in the Southern blot test were DNA samples from a male and female with normal
CGG size alleles and male and female FM carriers as described in a previous publication [2]. Five µg
of DNA were digested with the methylation-sensitive enzyme combination of NruI/HindIII. The DNA
probe Pfxa3a was radio-labelled with P32 (Random primer DNA labelling kit, TAKARABIO, Otsu,
Japan) and used to detect FMR1 allele-specific restriction fragments by autoradiography as previously
described [22]. The AmplideX™ FMR1 PCR Kit (Asuragen, Austin, TX, USA) was used to confirm
CGG triplet repeat sizing and to perform methylation analysis of two HpaII sites: 5′ and 3′ of the CGG
expansion using blood DNA.
The Sequenom MALDI-TOF MS EpiTYPER system (Sequenom, USA) and Methylation Specific
Quantitative Melt Analysis (MS-QMA) were used to analyse mean methylation of the fragile X related
epigenetic element 2 (FREE2, located 3′ of the CGG repeat) in blood, buccal, and saliva samples as
previously described [23]. Specifically, duplicate bisulfite conversions were performed for each DNA
sample, with each conversion analysed twice using the EpiTYPER system and MS-QMA. The average
of the four methylation output measurements per sample was used as a summary measure of mean
FREE2 methylation presented in Figure 1.
FMR1 mRNA analysis was performed using the relative standard curve real-time PCR method,
where the mean of FMR1-5′ and FMR1-3′ assay outputs was normalized to average expression of three
internal control genes (GUS, EIF4A2, and SDHA), as previously described [11]. For each sample, RNA
was reverse transcribed in two separate cDNA reactions and then each was analysed in two separate
real time-PCR reactions. The mean of the four arbitrary unit outputs was used as a summary measure
for FMR1 mRNA expression for each sample.
2.4. Ruling Out Other Causes of Ataxia
PCR and fragment analyses were used to examine repeat regions associated Friedreich’s ataxia
(FA) and spinocerebellar ataxias (SCA) as part of the molecular diagnostics follow-up, using standard
diagnostic protocols as previously described [24,25].
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Figure 1. Molecular results. (A) Organization of the FMR1 5′ region  including the CGG expansion 
(sequence numbering from GenBank L29074 L38501) in relation to FMR1 and ASFMR1 transcription 
start  sites  (the  broken  lines  indicate  spliced  out  regions),  fragile  X  related  epigenetic  element  2 
(FREE2), the FMR1 CpG island and methylation sensitive restriction site NruI analysed using routine 
fragile X Southern blot testing, two HpaII sites targeted by Amplidex methylation PCR. The FREE2 
region is located downstream of the CGG expansion, at the exon 1/intron1 boundary and includes 12 
CpG sites. (B) Methylation sensitive Southern blot analysis of the NruI restriction site within FMR1 
CpG island in blood. The DNA sample in question from the fragile X syndrome (FXS) male suspected 
of fragile X associated tremor/ataxia syndrome (FXTAS) is in lane 5. Comparator DNA sized using 
standard CGG PCR1 from: (1) a typical male and a female (CGG < 44) are in lanes 1 and 2; (2) full 
mutation (FM) male with a 100% methylated 613 CGG allele is in lane 3; (3) FM female with a 100% 
methylated 580 CGG allele is in lane 4. (C) Mean methylation output ratio of CpG sites located within 
the FREE2 region. Assessed using MALDI‐TOF MS and MS‐QMA2. Note: the error bars for reference 
ranges represent one standard deviation from the mean FREE2 methylation in blood of male controls 
(CGG < 44); Premutation (PM) males (56–170 CGGs); FM males with typical FXS (213–2000 CGGs), 
and  four  atypical  “high  functioning” unmethlyated  full mutation  (UFM) males  by  Southern  blot 
(CGG 200–637 CGG). The reference samples were co‐run with DNA from the FXS male case suspected 
of FXTAS from blood, buccal, and saliva samples in question. (D) FMR1 mRNA assessed using real‐
time PCR relative standard curve method. Amplidex PCR targeting methylation of two HpaII sites. 
(E)  Hexachloto‐Fluorescein  (HEX)  and  (F)  Fluorescein‐Amidite  (FAM)  channels  from  capillary 
electrophoresis of the DNA from the blood of the male case in question. Note: red arrows indicate 
presence  of  positive  FM  alleles  with  methylated  HpaII  sites  and  the  control  digestion  (HpaII 
methylation independent). 
Initial CGG repeat sizing in all samples was performed using polymerase chain reaction (PCR) 
as previously described [21]. Methylation‐sensitive Southern blot was used to confirm presence of a 
FM allele and  to perform methylation analysis of  the NruI restriction site  located within  the CpG 
Figure 1. Molecular results. (A) Organization of the FMR1 5′ region including the CGG expansion
(sequence numbering from GenBank L29074 L38501) in relation to FMR1 and ASFMR1 transcription
start sites (the broken li es indicate spliced out regions), fragile X related epigenetic eleme t 2 (FREE2),
the FMR1 CpG island and methylation sensitive r str ction site NruI analysed using routine fragile X
Southern blot testing, two HpaII sites targeted by AmplideX methylation PCR. The FREE2 region is
located downstream of the CGG expansion, at the exon 1/intron1 boundary and includes 12 CpG sites.
(B) Methylation sensitive Southern blot analysis of the NruI restriction site within FMR1 CpG island in
blood. The DNA sample in question from the fragile X syndrome (FXS) male suspected of fragile X
associated tremor/ataxia syndrome (FXTAS) is in lane 5. Comparator DNA sized using standard CGG
PCR1 from: (1) a typical male and a female (CGG < 44) are in lanes 1 and 2; (2) full mutation (FM) male
with a 100% methylated 613 CGG allele is in lane 3; (3) FM female with a 100% methylated 580 CGG
allele is in lane 4. (C) Mean methylation output ratio of CpG sites located within the FREE2 region.
Assessed using MALDI-TOF MS and MS-QMA2. Note: the error bars for reference ranges repr sent
one standard deviation from the mean FREE2 methylation in blood f male controls (CGG < 44);
Premutation (PM) males (56–170 CGGs); FM ales with typical FXS (213–2000 CGGs), and four atypical
“high functioning” unmethlyated full mutation (UFM) males by Southern blot (CGG 200–637 CGG).
The reference samples were co-run with DNA from the FXS male case suspected of FXTAS from blood,
buccal, and saliva samples in question. (D) FMR1 mRNA assessed using real-time PCR relative standard
curve method. AmplideX PCR targeting methylation of two HpaII sites. (E) Hexachloto-Fluorescein
(HEX) and (F) Fluorescein-Amidite (FAM) channels from capillary electrophoresis of the DNA from
the blood of the male case in question. Note: red arrows indicate presence of positive FM alleles with
methylated HpaII sites and the control digestion (HpaII methylation independent).
3. R sults and Discussion
3.1. Clinical Features and Medical History
A 38 year old intellectually disabled male with a previous diagnosis of fragile X syndrome
presented to a neurology clinic with a hi tory of intermitte t tremor and increasi g unsteadiness
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over the previous several months. His medical history included type 2 diabetes mellitus and
hyperthyroidism due to Grave’s disease. His medications included metformin, gliclazide, insulin,
telmisartan, and rabeprazole. His living arrangements were semi-supervised in a flat downstairs from
his parents. He has no family history of other movement disorders, including essential tremor; he has
only consumed small amounts of alcohol in social settings and there was no history of substance abuse.
His physical examination demonstrated a high frequency of up-down action tremor without any
resting tremor, truncal tremor, titubation, or extrapyramidal signs. Although he had no cerebellar signs
in his limbs or nystagmus, he demonstrated a slightly wide-based gait and was unable to complete
tandem gait suggesting a mild degree of cerebellar dysfunction. No other involuntary movements
or pyramidal signs or apraxia were present. His brain magnetic resonance imaging revealed mild
cerebellar atrophy (Figure 2).
Formal assessments of cognitive and behavioural impairments previously associated with the FXS
phenotype were performed at 38 years of age, six months after the initial visit. While he was cognitively
impaired with full scale IQ (FSIQ) of 50 [26], the score was above the mean FSIQ of 41.2, previously
reported in a sample of 51 males with fully methylated FM alleles [27]. However, his overall Autism
Diagnostic Observational Schedule-2 (ADOS-2) calibrated severity score (CSS) of 9 [28,29] indicated
that he has significant autism spectrum symptomology. His Aberrant Behaviour Checklist Community
(ABC-C) scores on Stereotypy and Inappropriate Speech were consistent with individuals with FXS [29]
and with the repetitive speech and behaviours observed during the ADOS-2 assessment. However,
his ABC-C score on three subscales, (Irritability, Lethargy, and Hyperactivity) were much lower than
the mean scores obtained by adult males with FXS [30]. His scores on the Adult Behaviour Checklist
(ABCL) were in the normal range for the Externalizing Scale, borderline range for the Internalizing
Scale with Somatic Complaints score in the clinically significant range [31].
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Figure 2. Magnetic resonance imaging of the brain. (A) T1 weighted sagittal view; and (B) T2 weighted 
axial view. Both images demonstrate the normal appearance of the cerebellum 
Blood  biochemistry  investigations,  including  thyroid  function  tests,  vitamin  B12,  folate, 
autoimmune, and paraneoplastic antibody panel, were all within normal limits. Despite a history of 
suboptimally controlled diabetes, there was no evidence of sensory or motor neuropathy on the nerve 
conduction studies, ruling out other possible causes of tremor and ataxia. While PCR based testing 
for other causes of ataxia did not support Friedrich’s ataxia or spinocerebellar ataxias type 1, 2, 3, 6, 
and 7, it is possible that the FXS patient has another neurological disorder that would explain the 
early onset ataxia. 
3.2. Genetic Testing 
The original diagnostic investigation for FXS at 14 years of age, based on morphological features 
and cytogenetic testing of cells expressing the Xq27.3 fragile site, was negative. At 38 years of age, he 
was again referred for FXS testing after his nephew was diagnosed with this syndrome. The follow‐
up  testing  using  Southern  blot  revealed  a  FM  expansion  but  did  not  use  methylation‐sensitive 
enzyme/s. Methylation sensitive Southern blot analysis performed that same year  identified a FM 
allele of 480 CGG repeats that had a 100% methylated NruI site within the FMR1 CpG island (Figure 
1B). This, at first, appeared to rule out the presence of PM or unmethylated FM alleles. However, 
methylation of the FREE2 region in blood, saliva, and buccal cells using MALDI‐TOF MS and MS‐
QMA  revealed  partial  methylation  of  the  FMR1  promoter  (60%–70%).  Presence  of  partially 
methylated FM alleles was further confirmed by (i) Amplidex TP‐mPCR through analysis of HpaII 
site methylation on either side of the CGG repeat (72% methylation) (Figure 1F) and (ii) Analysis of 
FMR1 mRNA levels in PBMCs revealing presence of transcription at 11% of the control group median 
levels. This suggested that FMR1 mRNA was not completely silenced in some FM alleles that could 
explain (i) RNA toxicity at least in a minority of cells and (ii) observed symptoms of ataxia. This is 
consistent with another 33 year old male case where tissue mosaicism for FM methylation, similarly, 
did not show FMR1 mRNA levels above the normal range, however, he had clinical and MRI findings 
consistent with FXTAS [19]   
4. Conclusions 
Figure 2. Magnetic resonance imaging of the brain. (A) T1 weighted sagittal view; and (B) T2 weighted
axial view. Both images demonstrate the normal appearance of the cerebellum.
Blood biochemistry investigations, including thyroid function tests, vitamin B12, folate,
autoimmune, and paraneoplastic antibody panel, were all within normal limits. Despite a history of
suboptimally controlled diabetes, there was no evidence of sensory or motor neuropathy on the nerve
conduction studies, ruling out other possible causes of tremor and ataxia. While PCR based testing
for other causes of ataxia did not support Friedrich’s ataxia or spinocerebellar ataxias type 1, 2, 3, 6,
and 7, it is possible that the FXS patient has another neurological disorder that would explain the early
onset ataxia.
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3.2. Genetic Testing
The original diagnostic investigation for FXS at 14 years of age, based on morphological
features and cytogenetic testing of cells expressing the Xq27.3 fragile site, was negative. At 38 years
of age, he was again referred for FXS testing after his nephew was diagnosed with this
syndrome. The follow-up testing using Southern blot revealed a FM expansion but did not use
methylation-sensitive enzyme/s. Methylation sensitive Southern blot analysis performed that same
year identified a FM allele of 480 CGG repeats that had a 100% methylated NruI site within the FMR1
CpG island (Figure 1B). This, at first, appeared to rule out the presence of PM or unmethylated FM
alleles. However, methylation of the FREE2 region in blood, saliva, and buccal cells using MALDI-TOF
MS and MS-QMA revealed partial methylation of the FMR1 promoter (60%–70%). Presence of partially
methylated FM alleles was further confirmed by (i) AmplideX TP-mPCR through analysis of HpaII
site methylation on either side of the CGG repeat (72% methylation) (Figure 1F) and (ii) Analysis of
FMR1 mRNA levels in PBMCs revealing presence of transcription at 11% of the control group median
levels. This suggested that FMR1 mRNA was not completely silenced in some FM alleles that could
explain (i) RNA toxicity at least in a minority of cells and (ii) observed symptoms of ataxia. This is
consistent with another 33 year old male case where tissue mosaicism for FM methylation, similarly,
did not show FMR1 mRNA levels above the normal range, however, he had clinical and MRI findings
consistent with FXTAS [19].
4. Conclusions
This FXS patient demonstrated early onset ataxia without MRI changes beyond mild cerebellar
atrophy. While his Southern blot results showed a FM with complete methylation of the FMR1
promoter, from which it could be inferred that the gene was completely silenced in all of his cells, this
was inconsistent with the following results: (i) reduced but not silenced FMR1 transcription; (ii) blood
biochemistry results ruling out other causes of ataxia; (iii) his cognitive impairment being not as severe
as previously reported in most fully methylated FM males. All of this suggested that in this FXS
male, FM alleles in a proportion of cells had unmethylated FM alleles and thus were able to express
potentially toxic FMR1 mRNA. This was supported by FREE2 methylation testing in blood, buccal, and
saliva, AmplideX methylation testing, and FMR1 mRNA analysis in blood. Two potential explanations
for the discordance in the methylation results obtained between Southern blot and the other techniques
are: (i) the analytical sensitivity of Southern blot methylation analysis is 20% [23], meaning alleles that
are 80% methylated will appear as if they are 100% methylated; (ii) the NruI restriction site methylation
is different to methylation of the HpaII restriction sites targeted by AmplideX and the FREE2 region
targeted by MALDI-TOF MS and MS-QMA. Together this evidence supports the conclusion that
FMR1 mRNA is expressed from expanded FM alleles that may be toxic, even in individuals who
appear to have a fully methylated FM by the “gold standard” methylation-sensitive Southern blot test.
Furthermore, co-morbidity of FXS and ataxia may be more common than previously realised as ataxia
has been noted in some older FXS FM patients identified using methylation-sensitive Southern blot
in previously described cohorts [32]. We, therefore, propose that if an FXS patient develops ataxia,
additional testing be performed including DNA methylation analysis of multiple sites within the
FMR1 promoter (especially the FREE2 region) and in multiple tissues, along with testing for FMR1
expression analysis if RNA is available. This additional diagnostic information may better explain the
clinical phenotype and provide some assurance to the patients and their family that this is another
manifestation of the FMR1 PM or unmethylated FM alleles, rather than a new, unexplained aetiology.
Whether the underlying cause of this patient’s ataxia is the same as for FXTAS is unknown, but
follow-up study is justified to consider if his symptoms worsen.
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